F-18-fluorodeoxyglucose (FDG) positron-emission tomography of Echinococcus multilocularis liver lesions: Prospective evaluation of its value for diagnosis and follow-up during benzimidazole therapy

Infection

Volumn 35, Issue 1, 2007, Pages 11-18

  Stumpe, K D M ^a   Renner Schneiter, E C ^a,d   Kuenzle, A K ^a   Grimm, F ^b   Kadry, Z ^a,c   Clavien, P A ^a   Deplazes, P ^b   Von Schulthess, G K ^a   Muellhaupt, B ^a   Ammann, R W ^a   Renner, E L ^a,d  

^a UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^b UNIVERSITY OF ZURICH   (Switzerland)

^c PENN STATE MILTON S HERSHEY MEDICAL CENTER   (United States)

^d UNIVERSITY OF MANITOBA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ALBENDAZOLE; BENZIMIDAZOLE; FLUORODEOXYGLUCOSE; MEBENDAZOLE;

ADULT; AGED; ALVEOLAR ECHINOCOCCOSIS; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CYSTIC ECHINOCOCCOSIS; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; DRUG UPTAKE; ECHINOCOCCUS MULTILOCULARIS; FEMALE; FOLLOW UP; HUMAN; LIVER HYDATID CYST; LIVER INJURY; MALE; PARASITE VIABILITY; PARASITIC LIVER DISEASE; POSITRON EMISSION TOMOGRAPHY;

ADULT; AGED; ANIMALS; ANTHELMINTICS; BENZIMIDAZOLES; DIAGNOSIS, DIFFERENTIAL; ECHINOCOCCOSIS, HEPATIC; ECHINOCOCCUS MULTILOCULARIS; FEMALE; FLUORODEOXYGLUCOSE F18; HUMANS; LIVER; MALE; MIDDLE AGED; POSITRON-EMISSION TOMOGRAPHY; RADIOPHARMACEUTICALS; SENSITIVITY AND SPECIFICITY;

EID: 33847165661     PISSN: 03008126     EISSN: None     Source Type: Journal    
DOI: 10.1007/s15010-007-6133-9     Document Type: Article

References (21)

1. Pawlowski ZS, Eckert J, Vuitton DA, Ammann RW, Kern P, Craig P: Echinococcosis in humans: clinical aspects, diagnosis and treatment. In: Eckert J, Gemmell MA, Meslin FX, Pawlowski ZS (eds) WHO/OIE Manual on echinococcosis in humans and animals. World Organisation for Animal Health and WHO, Paris 2001; pp 20-71.
2. Eckert J, Deplazes P: Biological, epidemiological, and clinical aspects of echinococcosis, a zoonosis of increasing concern. Clin Microbiol Rev 2004; 17:107-135.
3. McManus DP, Zhang W, Li J, Bartley PB: Echinococcosis. Lancet 2003; 362:1295-1304.
4. Eckert J, Jacquier P, Baumann D, Raeber PA: Human echinococcosis in Switzerland, 1984-1992. Schweiz Med Wochenschr 1995; 125:1989-1998.
5. Ammann RW, Eckert J: Cestodes. echinococcus. Gastroenterol Clin North Am 1996; 25:655-689.
6. Kadry Z, Renner EC, Bachmann LM, Attigah N, Renner EL, Ammann RW, Clavien PA: Evaluation of treatment and long-term follow-up in patients with hepatic alveolar echinococcosis. Br J Surg 2005; 92:1110-1116.
7. Ammann RW, Hirsbrunner R, Cotting J, Steiger U, Jacquier P, Eckert J: Recurrence rate after discontinuation of long-term mebendazole therapy in alveolar echinococcosis (preliminary results). Am J Trop Med Hyg 1990; 43:506-515.
8. Ammann RW, Renner EC, Gottstein B, Grimm F, Eckert J, Renner EL: Immunosurveillance of alveolar echinococcosis by specific humoral and cellular immune tests: long-term analysis of the Swiss chemotherapy trial (1976-2001). J Hepatol 2004; 41:551-559.
9. Eckert J, Jacquier P: Viability testing of Echinococcus multilocularis metacestodes from untreated and treated patients. Arch Hidatiol 1991; 30:863-867.
10. Reuter S, Schirrmeister H, Kratzer W, Dreweck C, Reske SN, Kern P: Pericystic metabolic activity in alveolar echinococcosis: assessment and follow-up by positron emission tomography. Clin Inf Dis 1999; 29:1157-1163.
11. Reuter S, Buck A, Manfras B, Kratzer W, Seitz HM, Darge K, Reske SN, Kern P: Structured treatment interruption in patients with alveolar echinococcosis. Hepatology 2004; 39:509-517.
12. Kern P, Wen H, Sato N, Vuitton DA, Gruener B, Shao Y, Delabrousse E, Kratzer W, Bresson-Hadni S: WHO classification of alveolar echinococcosis: principles and application. Parasitol Int 2006; 55(Suppl):S283-287.
13. Zingg W, Renner-Schneiter EC, Pauli-Magnus C, Renner EL, van Overbeck J, Schlapfer E, Weber M, Weber R, Opravil M, Gottstein B, Speck RF: Swiss HIV Cohort Study: Alveolar echinococcosis of the liver in an adult with human immunodeficiency virus type-1 infection. Infection 2004; 32:299-302.
14. Schmidlin P: Improved iterative image reconstruction using variable projection binning and abbreviated convolution. Eur J Nucl Med 1994; 21:930-936.
15. Stumpe KD, Dazzi H, Schaffner A, von Schulthess GK: Infection imaging using whole-body FDG-PET. Eur J Nucl Med 2000; 27:822-832.
16. Stumpe KD, Notzli HP, Zanetti M, Kamel EM, Hany TF, Gorres GW, von Schulthess GK, Hodler J: FDG PET for differentiation of infection and aseptic loosening in total hip replacements: comparison with conventional radiography and three-phase bone scintigraphy. Radiology 2004; 231:333-341.
17. Bresson-Hadni S, Delabrousse E, Blagosklonov O, Bartholomot B, Koch S, Miguet JP, Andre Mantion G, Angele Vuitton D: Imaging aspects and non-surgical interventional treatment in human alveolar echinococcosis. Parasitol Int 2006; 55(Suppl):S267-272.
18. Vuitton DA, Zhang SL, Yang Y, Godot V, Beurton I, Mantion G, Bresson-Hadni S: Survival strategy of Echinococcus multilocularis in the human host. Parasitol Int 2006; 55(Suppl):S51-55.
19. Zhuang H, Yu JQ, Alavi A: Applications of fluorodeoxyglucose-PET imaging in the detection of infection and inflammation and other benign disorders. Radiol Clin North Am 2005; 43:21-134.
20. Rausch RL, Wilson JF, Schantz PM, McMahon BJ: Spontaneous death of Echinococcus multilocularis: cases diagnosed serologically (by Em2 ELISA) and clinical significance. Am J Trop Med Hyg 1987; 36:576-585.
21. Gottstein B, Saucy F, Deplazes P, Reichen J, Demierre G, Busato A, Zuercher C, Pugin P: Is high prevalence of Echinococcus multilocularis in wild and domestic animals associated with disease incidence in humans? Emerg Inf Dis 2001; 7:408-412.